|
|
Line 36: |
Line 36: |
| | | |
| | | |
− | <center>
| |
| | | |
| | | |
| + | <p> |
| + | The collection of parts described herein forms a modular platform to determine which of the enzymes of the fatty acid reductase complex is rate-limiting. Each permutation of the complex’s genes is compatible for coexpression with the LuxAB construct. This methodology of stoichiometric expression can also be used to determine rate-limiting steps in other metabolic systems. |
| + | </p> |
| + | <center> |
| <div id='groupparts' style='min-height:100px;width:700px;'><div style='width:300px;margin:2px;padding:20px;color:#394053;border:1px dashed red'>Loading.....</div></div> | | <div id='groupparts' style='min-height:100px;width:700px;'><div style='width:300px;margin:2px;padding:20px;color:#394053;border:1px dashed red'>Loading.....</div></div> |
| | | |
Line 49: |
Line 52: |
| <div class="post-content"> | | <div class="post-content"> |
| | | |
− | <p>
| + | |
− | The collection of parts described herein forms a modular platform to determine which of the enzymes of the fatty acid reductase complex is rate-limiting. Each permutation of the complex’s genes is compatible for coexpression with the LuxAB construct. This methodology of stoichiometric expression can also be used to determine rate-limiting steps in other metabolic systems.
| + | |
− | </p>
| + | |
| | | |
| </div> | | </div> |